Targeted treatment for Age-Related Macular Degeneration, Diabetic Retinopathy, and Macular Oedema. At Elpis Medical Centre, we use the latest diagnostic tools and proven medications to manage these conditions and preserve your vision.
Intravitreal injections are an effective treatment for several serious conditions that affect the macula — the central part of the retina responsible for sharp, detailed vision. If left untreated, these conditions can lead to significant and irreversible vision loss.
Age-Related Macular Degeneration (AMD)
AMD is a common condition in older adults that damages the macula. The more severe form — wet AMD — occurs when abnormal blood vessels grow beneath the retina, leaking fluid or blood and causing rapid vision loss. Intravitreal injections are the standard treatment for wet AMD.
Diabetic Retinopathy
A complication of diabetes that damages the retinal blood vessels. These vessels can leak blood or fluid, leading to swelling, vision changes, and — if untreated — blindness. Intravitreal injections help control inflammation and prevent further damage to the retina.
Macular Oedema
Swelling of the macula caused by fluid buildup, often associated with diabetes, retinal vein occlusions, or other retinal conditions. The swelling distorts vision, making it blurry or wavy. Intravitreal injections reduce this swelling and can significantly improve visual acuity.
The process begins with a comprehensive eye examination, including visual acuity testing and a detailed assessment of the retina. If we detect any abnormalities, we proceed with advanced diagnostic imaging:
Once the diagnosis is confirmed, we discuss your treatment plan in detail, including the recommended injection schedule and expected outcomes.
Intravitreal injections deliver medication directly into the vitreous cavity of the eye, allowing it to reach the retina quickly and at therapeutic concentrations. This targeted approach is far more effective than oral or topical medications for these conditions.
The goal of treatment is to:
We use a range of proven anti-VEGF (vascular endothelial growth factor) medications, selected based on your specific condition and clinical response:
Avastin (Bevacizumab)
Originally developed for oncology, Avastin is widely used to treat wet AMD, diabetic retinopathy, and macular oedema. It works by inhibiting the growth of abnormal blood vessels in the retina. Extensive clinical evidence supports its safety and effectiveness in ophthalmology.
Eylea (Aflibercept)
A specialised anti-VEGF agent that blocks abnormal blood vessel growth and reduces fluid leakage. Approved for wet AMD, diabetic retinopathy, and macular oedema, Eylea often allows for longer intervals between injections.
Lucentis (Ranibizumab)
Specifically designed for ophthalmic use and approved for wet AMD, diabetic retinopathy, and macular oedema. Lucentis helps prevent vision loss by targeting abnormal vessel growth and reducing retinal swelling.
Vabysmo (Faricimab)
A newer dual-action treatment that targets both abnormal blood vessel growth and inflammation simultaneously. This approach can manage wet AMD, diabetic retinopathy, and macular oedema with potentially fewer injections over time — improving convenience for patients.
Intravitreal injections are performed in our operation theatre under sterile conditions and take only a few minutes:
Most patients experience only mild discomfort afterward. You may rest briefly at the clinic, but you can usually return to your normal activities the same day. We will provide clear aftercare instructions and schedule your follow-up appointment.
These conditions require ongoing monitoring. After each injection, we use OCT imaging to assess the retina’s response to treatment and determine the optimal timing for your next appointment. Treatment intervals are personalised — some patients require monthly injections initially, while others can be extended to longer intervals as the condition stabilises.
Our goal is always to achieve the best possible visual outcome with the fewest injections necessary.
These conditions can progress without obvious symptoms, which is why regular eye examinations are critical — especially if you are over 50, have diabetes, or have a family history of macular disease.
Early detection allows us to intervene with intravitreal injections before significant vision loss occurs. With modern treatments like Avastin, Eylea, Lucentis, and Vabysmo, many patients are able to maintain or even improve their vision.
If you have any concerns about your eye health or are experiencing changes in your vision, please schedule an appointment with us. We are here to provide comprehensive care and the latest treatments to protect your sight.
All of our services are available through the Cyprus General Health System (GeSY) or privately.
Ελληνικά